RC10 High Quality Factory supply High Purity Powder 99% purity fast delivery Retatrutide Smg+cagrilintide 5mg
TDS
898757-96-5
Cosmetics Grade
99.9%
SHANGHAI
1
5mg 10mg 15mg 20mg 30mg 40mg 50mg 60mg vials
2030-06-01
Tirzepatide,Polypeptide
-
Product Description
-
Seller Information
-
DescriptionCertificatesBasic Info
-
Product Name:
Methanone, (3,4-dimethylphenyl)[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylmethyl)phenyl]-
Other Name:Methanone,(3,4-dimethylphenyl)[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-ylmethyl)phenyl]-
CAS No.:898757-96-5
Molecular Formula:C23H27NO3
InChIKeys:InChIKey=YCBQLPPQIKUZLF-UHFFFAOYSA-N
Molecular Weight:365.46500
Exact Mass:365.47
DSSTox ID:DTXSID60642864
Categories:
Characteristics-
PSA:
38.77000
XLogP3:3.81120
Density:1.19g/cm3
Boiling Point:533.7ºC at 760 mmHg
Flash Point:276.6ºC
Refractive Index:1.606
Research-
Class:
Amylin receptor (AMYR) / calcitonin receptor (CTR) agonist (long-acting amylin analog)
Status:Investigational — Phase 3 (REDEFINE program, CagriSema combination)
Mechanism:A novel long-acting, acylated amylin (islet amyloid polypeptide, IAPP) analog consisting of 38 amino acids. Cagrilintide activates the amylin receptor (AMYR) and calcitonin receptor (CTR), reducing food intake, delaying gastric emptying, and promoting satiety. Being developed as monotherapy and in fixed-dose combination with semaglutide (CagriSema) for obesity. Administered once weekly.
Activity note:Cagrilintide is a non-selective AMYR/CTR agonist. Specific EC50 values not publicly available; functional potency is comparable to native amylin at AMYR.
Source:MCE: Cagrilintide (CAS 1415456-99-3); Novo Nordisk REDEFINE program.
Clinical Development:
References-
PubChem:Literature:
MCE: Cagrilintide (CAS 1415456-99-3); ClinicalTrials.gov: REDEFINE-1 (NCT05249895); Novo Nordisk: EASD 2025 Cagrilintide data presentation
Disclaimer:Cagrilintide is NOT FDA-approved or EMA-approved. It is in Phase 3 clinical trials (REDEFINE program). This listing is for industrial and laboratory research use only. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
Tirzepatide,Polypeptide
-
Location:
Yiwu City, Zhejiang Province
-
Payment Terms:
TT against copy of documents,D/P,D/A,O/A,TT against B/L draft before shipment,100% TT in advance
-
Average lead Time:
5
-
Total Employees:
5-10
-
Year of Establishment:
2025
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
